How to Audit Biologic Tissue Banks for FDA 361 Compliance

Auditing biologic tissue banks for FDA Section 361 compliance requires verifying active FDA Establishment Registration (FEI), reviewing the lab’s standard operating procedures against the four criteria of 21 CFR 1271.10(a), and inspecting third-party sterility and donor eligibility records. Medical practices must confirm that a manufacturer's human cells, tissues, and cellular and tissue-based products (HCT/Ps) are minimally manipulated and marketed strictly for homologous use without creating systemic effects, while checking the FDA compliance database for any history of Form 483 observations or Untitled Letters.

For medical practice managers, procurement of regenerative biologics—such as Wharton’s Jelly, amniotic allografts, cord blood, and extracellular vesicles—carries distinct regulatory responsibilities. Unlike standard medical consumables, sourcing HCT/Ps requires rigorous supply chain qualification. When a clinic administers a product that the FDA later determines is an unapproved biological drug rather than a compliant Section 361 tissue, the practice faces operational disruption, financial loss from seized or unusable inventory, and potential reputational liability. Establishing a standardized vendor audit protocol protects the clinic and ensures continuity of care.

Understanding the Regulatory Baseline: Section 361 vs. Section 351

Before requesting documentation from a supplier or tissue bank, practice administrators must understand the regulatory distinction under the Public Health Service (PHS) Act. The FDA regulates HCT/Ps under two primary tiers within 21 CFR Part 1271.

Products regulated solely under Section 361 of the PHS Act do not require premarket approval (such as an Investigational New Drug application or Biologics License Application), provided they meet all four strict criteria outlined in 21 CFR 1271.10(a):

1. Minimal Manipulation: For structural tissue, processing must not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. For cells or nonstructural tissues, processing must not alter the relevant biological characteristics.
2. Homologous Use Only: The product must perform the same basic function or functions in the recipient as in the donor, as reflected by the manufacturer's labeling, advertising, and objective intent.
3. No Combination with Another Article: The HCT/P cannot be combined with other active articles, except for water, crystalloids, or specific sterilizing, preserving, or storage agents.
4. No Systemic Effect: The product does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function (unless intended for autologous use, allogeneic use in a first- or second-degree blood relative, or reproductive use).

If a biologic fails to meet even one of these four pillars, it defaults to regulation under Section 351 as a drug, device, or biological product, which legally requires an active IND or BLA to be distributed and administered clinically. An effective vendor audit is designed to confirm that the tissue bank operates strictly within the boundaries of 21 CFR Part 1271—or holds the appropriate Section 351 clearances—and follows Good Tissue Practice (cGTP) standards.

Step-by-Step Checklist: How to Audit Biologic Tissue Banks for FDA Section 361 Compliance

When evaluating a new manufacturer or reviewing current inventory for regenerative medicine practices, practice managers should require a complete compliance dossier before signing a purchasing agreement. Use the following checklist to structure your vendor qualification workflow:

• Verify Active FDA Establishment Registration: Request the processing lab's FDA Establishment Identifier (FEI) number. Cross-reference this number directly in the public FDA Human Cell and Tissue Establishment Registration (HCTERS) database. Confirm that their registration status is "Active," verify the specific tissue types they are registered to process, and ensure the physical address matches the facility listed on their product packaging.
• understand the Limits of "FDA Registered": A critical red flag in vendor vetting is a sales representative claiming a Section 361 product is "FDA Approved." Section 361 products are registered, not approved. Registration simply means the facility has notified the FDA of its operations; it is not an endorsement of product compliance. Compliant vendors represent their status accurately.
• Conduct an FDA Enforcement and Warning Letter Search: Search the FDA’s public inspections and compliance databases using both the parent company name and any DBA entities. Check for recently issued Form FDA 483 (Inspectional Observations), Warning Letters, or Untitled Letters. If a 483 exists, request the laboratory's formal Corrective and Preventive Action (CAPA) response and proof of closeout.
• Audit Donor Eligibility and Infectious Disease Screening Protocols: Under 21 CFR Part 1271 Subpart C, tissue banks must maintain strict donor screening protocols. Request a sample (redacted) Donor Eligibility Summary and Certificate of Analysis (CoA). Verify that maternal donors for birth-tissue products are screened for relevant communicable disease agents and diseases (RCDADs) using FDA-licensed, approved, or cleared donor screening tests at a CLIA-certified laboratory.
• Confirm Current Good Tissue Practice (cGTP) and Sterility Testing: Review how the facility prevents the introduction, transmission, or spread of communicable diseases under Subpart D. Require documentation showing that every batch or lot undergoes USP <71> sterility testing and endotoxin testing prior to release. Ask whether the product is held in quarantine until final sterility results are confirmed.
• Evaluate Labeling, Promotional Materials, and Objective Intent: Because the "homologous use" requirement is evaluated based on the manufacturer's objective intent, you must audit the vendor’s marketing collateral, website, and package inserts. If a tissue bank markets an amniotic fluid or Wharton’s Jelly product with explicit claims to treat specific systemic diseases or regenerate cartilage in orthopedic joints, the FDA may cite those claims as evidence of non-homologous intent, instantly reclassifying the product as an unapproved Section 351 drug.
• Verify Cold-Chain Logistics and Adverse Event Tracking: Request the vendor's standard operating procedures for temperature-controlled shipping validation, tissue tracking (from donor to recipient), and adverse reaction reporting. Your clinic must be able to log tissue identification numbers into patient charts and trace them back to the tissue bank seamlessly in the event of a recall.

Clinical Perspective: Why Compliance Audits Matter to Treating Physicians

While the practice manager typically manages vendor onboarding, the compliance audit directly impacts the treating clinician across specialties such as orthopedics, pain management, and aesthetics. For physicians, the primary concerns are patient safety, medical malpractice coverage, and clinical predictability.

First, medical professional liability insurance policies frequently contain exclusions for the administration of unapproved drugs or products sourced from non-compliant manufacturers. If a physician administers a biologic that the FDA has flagged via a Warning Letter as an unapproved Section 351 drug, the clinician may inadvertently jeopardize their coverage in the event of an adverse patient outcome.

Second, cGTP compliance directly governs biological consistency. A tissue bank that cuts corners on donor screening, cryo-preservation curves, or cleanroom validation (ISO Class 5/7 environments) will deliver inconsistent allografts. Clinicians rely on intact structural extracellular matrices, predictable handling characteristics, and verified sterility to minimize post-procedural inflammatory flares or infections. Furthermore, accrediting bodies such as AATB (American Association of Tissue Banks), while voluntary, provide an additional layer of peer-reviewed operational auditing that reassures physicians of the tissue's quality and processing integrity.

Streamlining Procurement Through a Vetted Medical Distributor

Executing a comprehensive 21 CFR Part 1271 audit for multiple individual laboratories requires significant administrative time and regulatory familiarity. Many practice managers mitigate this burden by partnering with an established, licensed medical distributor rather than contracting piecemeal with unfamiliar labs.

At Dallas Regenerative Solutions, operating as a licensed Texas medical device distributor (License #1002308) since 2016, vendor due diligence is built into our curation process. Before onboarding any biologic manufacturer or regenerative technology partner, our team verifies establishment registrations, audits batch testing protocols, and reviews marketing compliance so that clinics can focus on patient care and workflow integration.

What This Means for Your Practice

To protect your practice and standardize your regenerative supply chain, implement the following operational action items this quarter:

1. Build a Compliance Binder for Current Inventory: Pull the lot numbers and manufacturer details for every biologic currently in your clinic's freezer or storage cabinet. Verify each lab’s active FEI number in the FDA HCTERS database and print the confirmation pages for your internal records.
2. Standardize Certificate of Analysis (CoA) Archiving: Ensure your clinical staff does not accept or log a biologic shipment into inventory unless it is accompanied by a lot-specific Certificate of Analysis and tissue tracking manifest.
3. Audit Your Own Practice Marketing: Ensure your clinic’s patient-facing brochures, consent forms, and website copy align with the manufacturer’s compliant labeling and do not make unapproved disease-treatment claims that violate Section 361 guidelines.

If you are evaluating your current biologic vendors or looking to expand your regenerative service line with vetted allografts and technologies, contact our team to schedule an operational consultation.